Published On: Thu, Aug 25th, 2016

Cannabis Science Inc. (OTC: CBIS) Releases Inhalant Medication to Fight Asthma/COPD

An unlikely entrant to the asthma/COPD inhalant medication has entered the arena. Cannabis Science (OTC: CBIS) has begun working with initial patients to test its cannabinoid-based inhalant medication. This observational study has been designed to accumulate valuable data and lead the company to clinical trials in the state of California. Fortunately, there is already a good deal of scientific research backing the efficacy of cannabis as an asthma/COPD treatment. They have been shown to relieve inflammation, kill microbes, support the immune system, relieve pain, and act as an expectorant, all while lending few side effects to patients.

The asthma treatment market is expecting to reach $23B by 2023, according to ReportsnReports, and GBI Research determined the COPD market should exceed $15.6B by 2019. With these two high-growth markets well within the company’s reach, there has never been a better time to start working towards trials. Many patients are tired of the harmful side effects of steroid-based treatments, and would remain open minded to opportunities to use a drug with fewer harmful side effects.

Fortunately, the treatments will be consumable with the use of a nebulizer rather than relying on smoking, which is (obviously) not good for patients with respiratory issues. This form of ingestion is safer for the lungs and is much less irritating, physically.

© Copyright 2016 OTC News Magazine. All rights reserved.